These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22931248)

  • 1. Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer.
    Létourneau IJ; Quinn MC; Wang LL; Portelance L; Caceres KY; Cyr L; Delvoye N; Meunier L; de Ladurantaye M; Shen Z; Arcand SL; Tonin PN; Provencher DM; Mes-Masson AM
    BMC Cancer; 2012 Aug; 12():379. PubMed ID: 22931248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer.
    Grisham RN; Iyer G; Sala E; Zhou Q; Iasonos A; DeLair D; Hyman DM; Aghajanian C
    Int J Gynecol Cancer; 2014 Jul; 24(6):1010-4. PubMed ID: 24978709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of three new serous epithelial ovarian cancer cell lines.
    Ouellet V; Zietarska M; Portelance L; Lafontaine J; Madore J; Puiffe ML; Arcand SL; Shen Z; Hébert J; Tonin PN; Provencher DM; Mes-Masson AM
    BMC Cancer; 2008 May; 8():152. PubMed ID: 18507860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Efficacy of Low-Dose Paclitaxel Added to Combination Chemotherapy of Carboplatin and Gemcitabine or Pegylated Liposomal Doxorubicin.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Hanaoka T; Hasegawa K; Fujiwara K
    Int J Gynecol Cancer; 2016 Mar; 26(3):443-8. PubMed ID: 26807640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.
    Stringer-Reasor EM; Baker GM; Skor MN; Kocherginsky M; Lengyel E; Fleming GF; Conzen SD
    Gynecol Oncol; 2015 Sep; 138(3):656-62. PubMed ID: 26115975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
    Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
    Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
    Sehouli J; Chekerov R; Reinthaller A; Richter R; Gonzalez-Martin A; Harter P; Woopen H; Petru E; Hanker LC; Keil E; Wimberger P; Klare P; Kurzeder C; Hilpert F; Belau AK; Zeimet A; Bover-Barcelo I; Canzler U; Mahner S; Meier W
    Ann Oncol; 2016 Dec; 27(12):2236-2241. PubMed ID: 27789470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Grabowski JP; Harter P; Heitz F; Pujade-Lauraine E; Reuss A; Kristensen G; Ray-Coquard I; Heitz J; Traut A; Pfisterer J; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):457-62. PubMed ID: 26807488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
    Matulonis U; Campos S; Duska L; Fuller A; Berkowitz R; Gore S; Roche M; Colella T; Lee H; Seiden MV; ;
    Gynecol Oncol; 2003 Nov; 91(2):293-8. PubMed ID: 14599858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer.
    Eng KH; Hanlon BM; Bradley WH; Szender JB
    Gynecol Oncol; 2015 Nov; 139(2):228-35. PubMed ID: 26383827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
    Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
    Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
    Williams J; Lucas PC; Griffith KA; Choi M; Fogoros S; Hu YY; Liu JR
    Gynecol Oncol; 2005 Feb; 96(2):287-95. PubMed ID: 15661210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine and carboplatin treatment in patients with relapsing ovarian cancer.
    Sufliarsky J; Chovanec J; Svetlovska D; Minarik T; Packan T; Kroslakova D; Lalabova R; Helpianska L; Horvathova D; Sevcik L; Spacek J; Laluha A; Tkacova V; Malec V; Rakicka G; Magdin D; Jancokova I; Dorr A; Stresko M; Habetinek V; Koza I
    Neoplasma; 2009; 56(4):291-7. PubMed ID: 19473054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of topotecan and cisplatin as first line chemotherapy in epithelial ovarian cancer].
    Meng LH; Kong BH; Zhang YZ; Yang XS; Wang LJ; Su SL; Jiang J; Cui BX; Wang B
    Zhonghua Fu Chan Ke Za Zhi; 2007 Oct; 42(10):683-7. PubMed ID: 18241544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer.
    Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT
    Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols.
    Sattar S; Ahmad M; Saeed H; Saleem Z; Danish Z; Akhlaq M
    Acta Pharm; 2019 Mar; 69(1):87-97. PubMed ID: 31259718
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
    Thigpen T
    Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.